Informatie:
Fout:
ID
34565
Beschrijving
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone; ODM derived from: https://clinicaltrials.gov/show/NCT01516424
Link
https://clinicaltrials.gov/show/NCT01516424
Trefwoorden
Versies (1)
- 19-01-19 19-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
19 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Schizophrenia NCT01516424
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Similar models
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
subject met dsm-iv-tr criteria for a primary diagnosis of schizophrenia
boolean
ID.2
Item
patients are 18≤age≤65 years of age on the day when informed consent is obtained.
boolean
ID.3
Item
subject had a panss total score ≥70 and 120≥ at screening
boolean
ID.4
Item
subject had a score ≥4 on the panss at screening and baseline.
boolean
ID.5
Item
subjects are willing and able to comply with study protocol including treatment in hospital.
boolean
ID.6
Item
subjects or their legal guardians have signed the written informed consent form.
boolean
ID.7
Item
the subject was treatment with other investigate product within 30 days.
boolean
ID.8
Item
subject had a history of treatment with long-acting drug for anti schizophrenia within 56 days.
boolean
ID.9
Item
subject had a history of treatment with clozapine within 28 days.
boolean
ID.10
Item
subject with parkinson disease,etc
boolean